US › Healthcare

ProMIS Neurosciences Inc. (PMN)

US · Healthcare · Biotechnology

$13.46+4.50%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-11.7M

EPS

$-1.28

EPS estimate

$-1.45

EPS came in at -1.28 against a street estimate of -1.45 — a beat of 11.7%.

Key statistics

Market cap

$115.6M

Forward P/E

0.0

P/B

2.43

Book value

$5.51

EPS (TTM)

$-12.62

52-week high

$27.40

52-week low

$6.27

50-day MA

$13.96

200-day MA

$12.54

Beta

-0.22

Analyst view

Analysts rate ProMIS Neurosciences Inc. a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $44.00.

Shareholding

Insiders

11.87%

Institutions

77.26%

Largest institutional holders

Fund	Stake
HHG PLC	14.42%
Deep Track Capital, LP	9.32%
Wellington Management Company LLP	7.77%
Ally Bridge Group (NY) LLC	6.92%
Trails Edge Capital Partners, LP	6.21%
Woodline Partners LP	4.41%
Yu Fan	3.68%
Sphera Funds Management Ltd.	3.63%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ProMIS Neurosciences Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.